Table 5.
VP manipulations and cognitive, maternal, rewarding (selfstimulation), and aversive effects.
| Reference | VP Manipulation | System | Effects | Task | Result |
|---|---|---|---|---|---|
| Numan et al., 2005a | SCH 23390 | Dopamine | D1 Antagonist | Maternal Behavior (Pup retrieval) | No effect |
| Numan et al., 2005b | Muscimol | GABA | GABA-A Agonist | Maternal Behavior (Pup retrieval + Nursing duration) | Decrease |
| Numan et al., 2005b | VP muscimol (contralateral) + MPOA lesion (ipsilateral) | GABA | GABA-A Agonist | Maternal Behavior (Pup retrieval + Nursing duration) | Decrease |
| Swerdlow et al., 1990 | Picrotoxin | GABA | GABA-A Antagonist | Pre-pulse inhibition | Decrease |
| Swerdlow et al., 1990 | VP Muscimol + Acb DA | GABA | GABA-A Agonist | Disruption of Pre-pulse inhibition by Acb DA | Blocked |
| Kodsi and Swerdlow 1995a | Medial VP Picrotoxin | GABA | GABA-A Antagonist | Pre-pulse inhibition | Decrease |
| Kodsi and Swerdlow 1995a | Central and lateral VP Picrotoxin | GABA | GABA-A Antagonist | Pre-pulse inhibition | No effect |
| Kodsi and Swerdlow 1995a | 2-OH-saclofen | GABA | GABA-B Antagonist | Pre-pulse inhibition | No effect |
| Kodsi and Swedlow 1995b | Picrotoxin | GABA | GABA-A Antagonist | Pre-pulse inhibition | Decrease |
| Swerdlow et al., 1990 | Picrotoxin | GABA | Antagonist | Pre-pulse inhibition | Decrease |
| Kretschmer and Koch 1998 | Lesion | NA | NA | Pre-pulse inhibition | No effect |
| Sipes and Geyer 1997 | DOI | Serotonin | 5-HT2A agonist | Pre-pulse inhibition | Decrease |
| Sipes and Geyer 1997 | MDL 100,907 | Serotonin | 5-HT2A antagonist | Pre-pulse inhibition | Increase |
| Ferry et al., 2000 | Lesion | NA | NA | Reversal learning | Decrease |
| Zhang et al., 2005 | Muscimol | GABA | GABA-A Agonist | Working memory task performance (lever) | Decrease |
| Zhang et al., 2005 | AMPA | Glutamate | AMPA agonist | Working memory task performance (lever) | Decrease |
| Zhang et al., 2005 | Lesion | NA | NA | Working memory task performance (lever) | Decrease |
| Zhang et al., 2005 | DAMGO | Opioid | Mu Agonist | Working memory task performance (lever) | Decrease |
| Kalivas et al., 2001 | AMPA | Glutamate | AMPA agonist | Working memory task performance (maze) | Decrease |
| Kalivas et al., 2001 | DAMGO | Opioid | Mu Agonist | Working memory task performance (maze) | Decrease |
| Kalivas et al., 2001 | VP DAMGO & MD GABA GABA-B saclofen | Opioid | Mu Agonist | Working memory task performance (maze) impairment | Blocked |
| Chrobak and Napier 2002 | Saline or aCSF | NA | NA | Working memory task performance (maze) | Decrease |
| Floresco et al., 1999 | Lidocaine | Sodium | Antagonist | Working memory task performance (maze) | Decrease |
| Huston et al., 1987 | Lesion | NA | NA | Brain Stimulation Reward | Decrease |
| Johnson and Stellar 1994b | Lesion | NA | NA | Brain Stimulation Reward | No effect |
| Johnson et al., 1993 | DAMGO | Opioid | Mu agonist | Brain Stimulation Reward | Mixed |
| Johnson and Stellar 1994a | DPDPE | Opioid | Delta agonist | Brain Stimulation Reward | Decrease |
| Waraczynski and Demco 2006 | Lidocaine | Sodium | Antagonist | Threshold of self-stimulation of Medial Forebrain Bundle | No effect |
| Ollman et al., 2014 | Neurotensin | Neurotensin | Agonist | Conditioned place preference | Established |
| Panagis and Spyraki 1996 | VP self-stimulation | Dopamine | Multiple | Threshold of self-stimulation and Systemic cocaine | Decrease |
| Panagis and Spyraki 1996 | VP self-stimulation | Dopamine | D3 agonist | Threshold of self-stimulation and Systemic 7-OH-DPAT | Decrease |
| Panagis and Spyraki 1996 | VP self-stimulation | Dopamine | D2 Antagonist | Threshold of self-stimulation and Systemic haloperidol | Increase |
| Panagis and Spyraki 1996 | VP self-stimulation | Dopamine | D1 Antagonist | Threshold of self-stimulation and Systemic SCH 23390 | Increase |
| Panagis and Spyraki 1996 | VP self-stimulation | Dopamine | D1 Antagonist | Threshold of self-stimulation and Systemic raclopride | Increase |
| Panagis and Spyraki 1996 | VP self-stimulation | Dopamine | D2 Antagonist | Threshold of self-stimulation and Systemic Sulpiride | Increase |
| Panagis and Kastellakis 2002 | VP self-stimulation | GABA | GABA-A Agonist | Threshold of self-stimulation and VTA muscimol | Increase |
| Panagis and Kastellakis 2002 | VP self-stimulation | GABA | GABA-B Agonist | Threshold of self-stimulation and VTA baclofen | Increase |
| Panagis and Kastellakis 2002 | VP self-stimulation | Glutamate | NMDA agonist | Threshold of self-stimulation and VTA NMDA | No effect |
| Panagis and Kastellakis 2002 | VP self-stimulation | Glutamate | AMPA agonist | Threshold of self-stimulation and VTA AMPA | No effect |
| Panagis et al., 1998 | VP self-stimulation | Opioid | Multiple | Threshold of self-stimulation and VTA morphine | Decrease |
| Smith et al., 2005 | Bicuculline | GABA | GABA-A Antagonist | Digging | Increase |
| Smith et al., 2005 | DAMGO | Opioid | Mu agonist | Digging | No effect |
| Mingote et al., 2008 | Muscimol | GABA | GABA-A Agonist | Effort task impairment induced by Acb Adenosine A2A agonist | Blocked |
| Smith et al., 2005 | Bicuculline | GABA | GABA-A Antagonist | Forepaw “defensive” treading | Increase |
| Smith et al., 2005 | DAMGO | Opioid | Mu agonist | Forepaw “defensive” treading | Increase |
| Lawrence et al., 2003 | Picrotoxin | GABA | GABA-A Antagonist | Latent Inhibition | No effect |
| Lawrence et al., 2003 | Muscimol | GABA | GABA-A Agonist | Latent Inhibition | No effect |
Manipulation refers to an intra-VP injection or VP lesion, unless stated otherwise.